This Article  • References  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Ali A. El-Domeiri, MD; Barbara Nika, RN; Wen-Cheng Hsia, MS; Ray Crispen, PhD; Tawfik Y. Sabet, PhD; Tapas K. Das Gupta, MD

Arch Surg. 1977;112(3):257-259.

Abstract
• The effect of systemic BCG therapy on advanced melanoma was studied in 42 patients with stage II and stage III disease. Evaluation of the immune response prior and during therapy revealed that patients who failed to convert a negative purified protein derivative (PPD) reaction and those having a low stimulation ratio of lymphocyte cultures had rapidly progressive disease and short survival. Neither tumor regression nor prolongation of survival could be appreciated in patients with stage III disease. Furthermore, aggravation of symptoms was observed in patients with visceral metastases. Fifty percent of the patients with stage II melanoma treated by operation and adjuvant immunotherapy had recurrent or metastatic disease within two years. No adverse effects were noted in patients with early disease who received adjuvant therapy. Two patients who had a full course of systemic BCG therapy developed severe reactions after intralesional injection of the vaccine. Further experience with various immunotherapeutic regimens and longer follow-up are necessary to evaluate its value in the early stages of melanoma.

(Arch Surg 112:257-259, 1977)

Author Affiliations
From the Division of Surgical Oncology, Abraham Lincoln School of Medicine, University of Illinois and Cook County Hospital, Chicago.

Footnotes
Accepted for publication Oct 7, 1976.

Reprint requests to Department of Surgery, Cook County Hospital, 1825 W Harrison St, Chicago, IL 60612 (Dr El-Domeiri).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati     What's this?